A federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic ...

Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key ...

CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its ...

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.

Novartis Pharmaceuticals Corp. convinced the Federal Circuit to temporarily block MSN Pharmaceuticals Inc. from launching a ...

Novartis could soon face generic competition for Entresto after judge's ruling.

In what is not exactly a win-win situation for the Indian generic firms, a recent federal court ruling in Delaware, USA, has ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its ...

Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...